COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD

Protocol No
IIT-ABEDIN-NEIHULIZUMAB
Principal Investigator
Sameem Abedin
Phase
I
Summary
To find out more about the side effects (problems and symptoms) of a new drug for acute graft-versus-host disease (aGVHD), neihulizumab, and what doses are safe for people to take.
Description
A Phase I Trial of Neihulizumab Monotherapy for Standard-Risk Acute GVHD
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL